BZM055, an Iodinated Radiotracer Candidate for PET and SPECT Imaging of Myelin and FTY720 Brain Distribution

被引:34
作者
Briard, Emmanuelle [1 ]
Orain, David [1 ]
Beerli, Christian [2 ]
Billich, Andreas [2 ]
Streiff, Markus [2 ]
Bigaud, Marc [2 ]
Auberson, Yves P. [1 ]
机构
[1] Novartis Inst BioMed Res, CH-4002 Basel, Switzerland
[2] Novartis Inst BioMed Res, Basel Autoimmun Transplantat & Inflammat Dis Area, CH-4002 Basel, Switzerland
关键词
imaging agents; iodine; myelin; positron emission tomography; SPHINGOSINE 1-PHOSPHATE RECEPTORS; IMMUNOMODULATORY DRUG FTY720; CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS; FINGOLIMOD; PHOSPHORYLATION; IMMUNE;
D O I
10.1002/cmdc.201000477
中图分类号
R914 [药物化学];
学科分类号
100705 [微生物与生化药学];
摘要
FTY720 (fingolimod, Gilenya (R)) is a sphingosine 1-phosphate (S1P) receptor modulator that shows significant therapeutic efficacy after oral administration to patients of multiple sclerosis. Because FTY720 does not contain any atom whose PET or SPECT radioisotope would have a half-life compatible with its pharmacokinetic properties, it cannot be used directly for imaging. Instead, we propose BZM055 as a surrogate tracer to study its pharmacokinetics and organ distribution in patients and, given that FTY720 accumulates in myelin sheaths, for myelin imaging. BZM055 (2a, 2-iodo-FTY720) can be easily radiolabeled with I-123 (for SPECT) or I-124 (for PET). Not only does it closely mimic the pharmacokinetics and organ distribution of FTY720, but also its affinity, selectivity for S1P receptors, phosphorylation kinetics, and overall physicochemical properties. [I-123]BZM055 is currently under development for clinical imaging.
引用
收藏
页码:667 / 677
页数:11
相关论文
共 26 条
[1]
ALBERT R, 2005, Patent No. 2005021503
[2]
BARILLA D, 2001, AM J TRANSPLANT S1, V1, P476
[3]
Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions [J].
Bartholomaeus, Ingo ;
Kawakami, Naoto ;
Odoardi, Francesca ;
Schlaeger, Christian ;
Miljkovic, Djordje ;
Ellwart, Joachim W. ;
Klinkert, Wolfgang E. F. ;
Fluegel-Koch, Cassandra ;
Issekutz, Thomas B. ;
Wekerle, Hartmut ;
Fluegel, Alexander .
NATURE, 2009, 462 (7269) :94-U104
[4]
Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases [J].
Billich, A ;
Bornancin, F ;
Dévay, P ;
Mechtcheriakova, D ;
Urtz, N ;
Baumruker, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (48) :47408-47415
[5]
The immune modulator FTY720 targets sphingosine 1-phosphate receptors [J].
Brinkmann, V ;
Davis, MD ;
Heise, CE ;
Albert, R ;
Cottens, S ;
Hof, R ;
Bruns, C ;
Prieschl, E ;
Baumruker, T ;
Hiestand, P ;
Foster, CA ;
Zollinger, M ;
Lynch, KR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (24) :21453-21457
[6]
Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology [J].
Brinkmann, Volker .
PHARMACOLOGY & THERAPEUTICS, 2007, 115 (01) :84-105
[7]
FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system [J].
Brinkmann, Volker .
BRITISH JOURNAL OF PHARMACOLOGY, 2009, 158 (05) :1173-1182
[8]
The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors [J].
Coelho, Rochelle P. ;
Payne, Shawn G. ;
Bittman, Robert ;
Spiegel, Sarah ;
Sato-Bigbee, Carmen .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 323 (02) :626-635
[9]
Multiple sclerosis [J].
Compston, Alastair ;
Coles, Alasdair .
LANCET, 2008, 372 (9648) :1502-1517
[10]
Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: Consequences for mode of action in multiple sclerosis [J].
Foster, Carolyn A. ;
Howard, Laurence M. ;
Schweitzer, Alain ;
Persohn, Elke ;
Hiestand, Peter C. ;
Balatoni, Balazs ;
Reuschel, Roland ;
Beerli, Christian ;
Schwartz, Manuela ;
Billich, Andreas .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 323 (02) :469-476